The role of advanced glycation end products in retinal microvascular leukostasis.

PURPOSE A critical event in the pathogenesis of diabetic retinopathy is the inappropriate adherence of leukocytes to the retinal capillaries. Advanced glycation end-products (AGEs) are known to play a role in chronic inflammatory processes, and the authors postulated that these adducts may play a role in promoting pathogenic increases in proinflammatory pathways within the retinal microvasculature. METHODS Retinal microvascular endothelial cells (RMECs) were treated with glycoaldehyde-modified albumin (AGE-Alb) or unmodified albumin (Alb). NFkappaB DNA binding was measured by electromobility shift assay (EMSA) and quantified with an ELISA: In addition, the effect of AGEs on leukocyte adhesion to endothelial cell monolayers was investigated. Further studies were performed in an attempt to confirm that this was AGE-induced adhesion by co-incubation of AGE-treated cells with soluble receptor for AGE (sRAGE). Parallel in vivo studies of nondiabetic mice assessed the effect of intraperitoneal delivery of AGE-Alb on ICAM-1 mRNA expression, NFkappaB DNA-binding activity, leukostasis, and blood-retinal barrier breakdown. RESULTS Treatment with AGE-Alb significantly enhanced the DNA-binding activity of NFkappaB (P = 0.0045) in retinal endothelial cells (RMECs) and increased the adhesion of leukocytes to RMEC monolayers (P = 0.04). The latter was significantly reduced by co-incubation with sRAGE (P < 0.01). Mice infused with AGE-Alb demonstrated a 1.8-fold increase in ICAM-1 mRNA when compared with control animals (P < 0.001, n = 20) as early as 48 hours, and this response remained for 7 days of treatment. Quantification of retinal NFkappaB demonstrated a threefold increase with AGE-Alb infusion in comparison to control levels (AGE Alb versus Alb, 0.23 vs. 0.076, P < 0.001, n = 10 mice). AGE-Alb treatment of mice also caused a significant increase in leukostasis in the retina (AGE-Alb versus Alb, 6.89 vs. 2.53, n = 12, P < 0.05) and a statistically significant increase in breakdown of the blood-retinal barrier (AGE Alb versus Alb, 8.2 vs. 1.6 n = 10, P < 0.001). CONCLUSIONS AGEs caused upregulation of NFkappaB in the retinal microvascular endothelium and an AGE-specific increase in leukocyte adhesion in vitro was also observed. In addition, increased leukocyte adherence in vivo was demonstrated that was accompanied by blood-retinal barrier dysfunction. These findings add further evidence to the thinking that AGEs may play an important role in the pathogenesis of diabetic retinopathy.

[1]  K Miyamoto,et al.  Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. , 2000, Investigative ophthalmology & visual science.

[2]  V. Monnier,et al.  Collagen Aging In Vitro by Nonenzymatic Glycosylation and Browning , 1984, Diabetes.

[3]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[4]  A. Schmidt,et al.  Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. , 1995, The Journal of clinical investigation.

[5]  L. Aiello.  Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. , 1998, Ophthalmic research.

[6]  V. Monnier,et al.  Mechanism of Protein Modification by Glyoxal and Glycolaldehyde, Reactive Intermediates of the Maillard Reaction (*) , 1995, The Journal of Biological Chemistry.

[7]  R. Perry,et al.  The gene family encoding the mouse ribosomal protein L32 contains a uniquely expressed intron-containing gene and an unmutated processed gene , 1984, Cell.

[8]  A. Schmidt,et al.  Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.

[9]  K. Miyarnoto.  Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition , 1999 .

[10]  Alan W. Stitt,et al.  Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. , 1997, The American journal of pathology.

[11]  S. Krungkrai,et al.  Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Aiello,et al.  Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Cooper,et al.  Mechanisms of diabetic vasculopathy: an overview. , 2001, American journal of hypertension.

[14]  A. Adamis,et al.  Sensitive blood-retinal barrier breakdown quantitation using Evans blue. , 2001, Investigative ophthalmology & visual science.

[15]  M. Matsumoto,et al.  The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  J. Baynes,et al.  Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging , 1996, Drugs & aging.

[17]  E. Diamandis,et al.  Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia. , 1997, Kidney international.

[18]  M. Lagarde,et al.  In vitro and in vivo alterations of enzymatic glycosylation in diabetes. , 1999, Life sciences.

[19]  T. Forst,et al.  The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[20]  B Kirchhof,et al.  Leukocyte-mediated endothelial cell injury and death in the diabetic retina. , 2001, The American journal of pathology.

[21]  E. Kohner,et al.  Activity of the glycosylating enzyme, core 2 GlcNAc (beta1,6) transferase, is higher in polymorphonuclear leukocytes from diabetic patients compared with age-matched control subjects: relevance to capillary occlusion in diabetic retinopathy. , 2000, Diabetes.

[22]  J. Baynes,et al.  N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. , 1997, The Biochemical journal.

[23]  A. Schmidt,et al.  Atherosclerosis and diabetes: The rage connection , 2000, Current atherosclerosis reports.

[24]  D. Archer,et al.  The effect of endothelin 1 on the retinal microvascular pericyte. , 1992, Microvascular research.

[25]  E. Friedman,et al.  Hemoglobin-AGE: a circulating marker of advanced glycosylation. , 1992, Science.

[26]  S. Schiekofer,et al.  The role of oxidative stress and NF‐κB activation in late diabetic complications , 1999, BioFactors.

[27]  H. Hammes,et al.  Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model , 1995, Diabetologia.

[28]  E. Diamandis,et al.  The serum concentration of the advanced glycation end-product Nε-(carboxymethyl)lysine is increased in uremia: Technical Note , 1997 .

[29]  P. Baeuerle,et al.  Induction of Oxidative Stress by Okadaic Acid Is Required for Activation of Transcription Factor NF-κB (*) , 1995, The Journal of Biological Chemistry.

[30]  E. Kohner,et al.  Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy , 1997, Diabetologia.

[31]  J. Baynes,et al.  Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. , 1986, The Journal of biological chemistry.

[32]  Alan W. Stitt,et al.  Atherogenesis and Advanced Glycation: Promotion, Progression, and Prevention a , 1997, Annals of the New York Academy of Sciences.

[33]  K. Matsumoto,et al.  Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor. , 2000, Diabetes.

[34]  J. Baynes,et al.  Glycoxidation and lipoxidation in atherogenesis. , 2000, Free radical biology & medicine.

[35]  K Miyamoto,et al.  Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). , 2000, The American journal of pathology.

[36]  G. Romeo,et al.  Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. , 2000, Investigative ophthalmology & visual science.

[37]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[38]  Alan W. Stitt,et al.  Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. , 1998, Diabetes.

[39]  G. Yancopoulos,et al.  VEGF-initiated blood-retinal barrier breakdown in early diabetes. , 2001, Investigative ophthalmology & visual science.

[40]  F. Numano,et al.  The Effect of Glucose and Advanced Glycosylation End Products on IL‐6 Production by Human Monocytes , 1994, Annals of the New York Academy of Sciences.

[41]  B. Veldhuisen,et al.  Nephrology Dialysis Transplantation Analysis of a large family with the second type of autosomal dominant polycystic kidney disease , 2005 .

[42]  H. Hammes,et al.  Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats , 1995, Diabetologia.

[43]  H. Pertoft,et al.  Separation of human monocytes on density gradients of Percoll. , 1980, Journal of immunological methods.

[44]  E. Agardh,et al.  Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. , 2000, Current eye research.

[45]  H. Hammes,et al.  Differential accumulation of advanced glycation end products in the course of diabetic retinopathy , 1999, Diabetologia.

[46]  G. Striker,et al.  Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[47]  T. Kern,et al.  Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. , 2001, Diabetes.

[48]  Alan W. Stitt,et al.  Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. , 2000, Molecular cell biology research communications : MCBRC.